SAB Biotherapeutics Announces New Appointments to its Board of Directors
16.12.2020 15:27:00 EET | Business Wire | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors.
“We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a pivotal time as we continue to advance a new class of immunotherapies that leverage the native human immune response and match the evolution of human disease. We look forward to their contributions as we develop our robust pipeline, spanning multiple therapeutic areas, using our novel technology platform.”
Dr. Mohindru is a senior biopharmaceutical executive with several years of industry leadership as well as Wall Street experience. Most recently, she was the CEO of CereXis, a clinical-stage biopharmaceutical company developing treatments for rare tumors. Previously, Dr. Mohindru was Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics (Nasdaq: CARA), a company focused on developing therapies for pruritus and pain. Earlier, she served as Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS), where she was instrumental in the development of overall strategy for its oncology focused pipeline. Dr. Mohindru also spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS. She also co-founded Immtox LLC, a privately-held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Currently, she also serves as a Member of the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Dr. Mohindru received her PhD in Neurosciences from Northwestern University.
Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing and business development, emerging markets strategy development and implementation. He currently operates his own consulting firm, MJ Turner Consulting, where he counsels biotech, pharma, venture capital and investment banking firms. He spent 27 years at Merck & Co. Inc., holding positions of increasing responsibility in Merck Research Laboratories before joining the company’s Executive Committee as Chief Strategy Officer. Since his retirement from Merck & Co., he is currently an Advisor to Bay City Capital, a San Francisco-based venture firm, to Bridge Medicines, a commercial incubator for early stage innovation based in New York City, and to Adagene, a China-based therapeutic antibody company. Dr Turner is also a member of the Board of EnGeneIC (Sydney, Australia), and the Chairman of the Board of LUNAC. He also serves on the Scientific Advisory Boards of Blade Therapeutics and Spinogenix. Additionally, Dr. Turner is a Senior Advisor to the Healthcare group of Lazard, a leading financial services and investment banking firm. He holds his PhD in Chemistry from the University of Sheffield.
“I am excited to have the opportunity to join the Board of SAB, to help foster the adoption of the company’s unique capabilities in meeting the therapeutic needs of both the current, and future pandemics,” said Mervyn Turner, PhD. “I also look forward to helping to drive the SAB platform into novel therapeutic areas outside infectious disease, where polyclonal antibody technology offers unique capabilities in areas of significant unmet medical need.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed with initial funding supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant and influenza. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005549/en/
Contact information
Melissa Ullerich
Tel: 605-695-8350
mullerich@sabbiotherapeutics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI-Driven Upgrade Cycle Expected to Fuel 8% Telecom Growth in 2026, NIQ Forecasts10.6.2026 14:00:00 EEST | Press release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 2026 Smartphone Forecast showing that an AI-driven upgrade cycle is expected to fuel 8% growth in the global telecom sector in 2026. As manufacturers accelerate investment in on-device AI and connected device ecosystems, consumers are increasingly prioritizing intelligence functionality, seamless integration, and premium experiences when choosing their next smartphone. The forecast suggests relatively stable conditions across the broader technology and durables market, with growth increasingly concentrated in premium segments. Europe is showing early signs of a new replacement cycle after two weaker years, while China is showing signals of modest growth despite subsidy rollbacks and a challenging comparison base. Insights from Mobile World Congress 2026 suggest a broader industry shift: smartphones are evolving from standalone communication devices into intelligent platforms that connect and orchestrate consu
Opensignal Expands Subscriber Analytics Solution, Available Globally10.6.2026 14:00:00 EEST | Press release
Opensignal® today announced the global availability of Opensignal Subscriber Analytics™, extending the solution to operators across Europe, Asia Pacific, Middle East, Africa, and the Americas, subject to market-specific availability. Operators can contact Opensignal directly to confirm availability details in their specific markets of interest. Opensignal Subscriber Analytics measures competitive subscriber switching between operators at the local market level, alongside base market share by operator and region, using the same methodology Opensignal applies across its full measurement platform. Opensignal draws that measurement from hundreds of millions of subscriber devices globally. Until now, this capability has been available to operators in the United States and Canada. The global expansion makes it accessible to operators across all regions Opensignal serves. "Operators have strong visibility into their own network and commercial performance, but almost none for their competitors
Data Center World Unveils the Inaugural Data Center World Europe 202610.6.2026 14:00:00 EEST | Press release
Data Center World, the premier event for the global data center ecosystem, unveils the launch of Data Center World Europe. Today, Data Center World Europe announces the Conference Agenda for the inaugural event. Over two days, Data Center World Europetackles the industry’s most urgent challenge: transforming Europe's data centre energy landscape. The event brings together leading operators, technologists, cloud providers, hyperscalers and energy management innovatorsto exchange actionable strategies and groundbreaking insights that drive measurable results. Attendees will leave equipped to overcome energy bottlenecks and drive the development of an AI-ready, sustainable future. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It will be co-located with the leading global network infrastructure event NetworkX. Register to attend here. Tara Gibb, Senior Director, Data Center World Europe said, “As the demand for A
SES to conduct share buyback transaction via acquisition of FDRs to meet obligations under its employee incentive programs10.6.2026 13:56:00 EEST | Press release
SES has decided to launch a buyback transaction for shares via acquisition of fiduciary depositary receipts (FDRs) to meet obligations under SES’s Equity Based Compensation Plan (EBCP). These FDRs will be repurchased on the basis of Article 430-15(3) of the law of 10 August 1915 on commercial companies, as amended, and will not be counted towards the 10% limit as authorized during the annual general meeting of shareholders held on April 2, 2026. Under this share buyback transaction via acquisitions of FDRs, SES may acquire up to 2,967,519 FDRs (ISIN LU0088087324) at market price for an aggregate amount not exceeding EUR 31,158,949.50. The share buyback transaction via acquisition of FDRs is expected to be completed before the date of the next annual general meeting of shareholders or sooner if the maximum number of repurchased shares is reached earlier. The buyback will be conducted in accordance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and
New Research Reveals the Next Wealth Management Divide: AI Rewards Firms Built to Scale10.6.2026 13:34:00 EEST | Press release
The next competitive divide in banking, wealth and asset management will not be defined by innovation alone, but by firms’ ability to scale it profitably. That is the central finding of new research that Objectway, a global wealthtech partner for banking, wealth and asset management firms, conducted in collaboration with FT Longitude, a specialist provider of thought leadership and research services. The report, Built to Scale, is based on a survey of 300 senior professionals across banks, wealth and asset managers in the UK, continental Europe and Canada. Altough digital transformation and AI adoption are advancing rapidly across the industry, many firms are struggling to translate investment into repeatable, profitable growth. The findings point to a market entering a new phase of competition, where scalable executionis becoming more important thaninnovation capacity alone. Reflecting on this shift, Luigi Marciano, Founder and Group CEO of Objectway, commented: “For years, the indust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom